Xiromed is introducing testosterone cypionate injection, the generic of Depo-Testosterone.
Testosterone cypionate injection is indicated for replacement therapy in males with conditions associated with symptoms of deficiency or absence of endogenous testosterone. N-Desalkylflurazepam
[Read more: Xiromed, Genzum unveil generic Naftin]
“Testosterone Cypionate Injection is the third product approval from Laboratorios Farmalan, our dedicated injectable hormonal facility in Leon, Spain,” said Rob Spina, CEO of Xiromed. “This approval bolsters our hormonal products portfolio, and we are pleased to offer another affordable treatment option to U.S. patients.”
Depo-Testosterone and its generics had a market value of $193.8 million for the 12-month period ending February 2023, according to IQVIA.
Bioidentical Testosterone [Read more: Xiromed unveils generic Extina]